title: The NeuroStar TMS device: conducting the FDA approved protocol for treatment of depression.
abstract: The Neuronetics NeuroStar Transcranial Magnetic Stimulation (TMS) System is a class II medical device that produces brief duration, pulsed magnetic fields. These rapidly alternating fields induce electrical currents within localized, targeted regions of the cortex which are associated with various physiological and functional brain changes. In 2007, O'Reardon et al., utilizing the NeuroStar device, published the results of an industry-sponsored, multisite, randomized, sham-stimulation controlled clinical trial in which 301 patients with major depression, who had previously failed to respond to at least one adequate antidepressant treatment trial, underwent either active or sham TMS over the left dorsolateral prefrontal cortex (DLPFC). The patients, who were medication-free at the time of the study, received TMS five times per week over 4-6 weeks. The results demonstrated that a sub-population of patients (those who were relatively less resistant to medication, having failed not more than two good pharmacologic trials) showed a statistically significant improvement on the Montgomery-Asberg Depression Scale (MADRS), the Hamilton Depression Rating Scale (HAMD), and various other outcome measures. In October 2008, supported by these and other similar results, Neuronetics obtained the first and only Food and Drug Administration (FDA) approval for the clinical treatment of a specific form of medication-refractory depression using a TMS Therapy device (FDA approval K061053). In this paper, we will explore the specified FDA approved NeuroStar depression treatment protocol (to be administered only under prescription and by a licensed medical profession in either an in- or outpatient setting).
authors.affiliation: Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center, USA. jhorvat2@bidmc.harvard.edu
authors.forename: Jared C
authors.initials: JC
authors.lastname: Horvath
authors.forename: John
authors.initials: J
authors.lastname: Mathews
authors.forename: Mark A
authors.initials: MA
authors.lastname: Demitrack
authors.forename: Alvaro
authors.initials: A
authors.lastname: Pascual-Leone
mesh_terms: D003863:Depression / Q000628:therapy*; D018795:Device Approval; D004558:Electric Stimulation / Q000295:instrumentation*; D006801:Humans; D050781:Transcranial Magnetic Stimulation / Q000295:instrumentation* / Q000592:standards*; D014481:United States; D014486:United States Food and Drug Administration